PHARM2FARM
11.3.2021 10:32:12 CET | Business Wire | Press release
A new anti-viral mask which kills 99.9% of Covid-19 virus within five minutes of contact has been launched today – offering an unparalleled level of protection against viruses not just for those around them but for the wearer too.
Aimed at all types of industry, from hospital and care homes, to schools, to the retail & leisure industries, Pro-Larva differs from conventional masks because, as well as protecting those around the wearer, it protects the wearer themselves, using revolutionary copper nanoparticle technology developed here in the UK.
Antony Legge, Chairman of the parent company Pharm2Farm explains: “Conventional surgical-type TR2 masks only block virus from exiting the mask – they don’t have an active mechanism for killing it once it’s trapped in the mask. Pro-Larva has been designed to use existing barrier technology but also to combine it with α-virion™, a copper nanoparticle technology that kills 99.9% of the virus once it is trapped in the mask.”
This viricidal layer is effective for up to seven hours. Current surgical masks are only effective for around two hours, which requires health care professionals in Intensive Care Units (ICUs) to wear between 4-10 masks per day.
Because of Pro-Larva’s longer effective life this greatly reduces the number of masks required, therefore reducing costs for the hospital or care home. Pro-Larva is also self-sterilising – killing Covid-19 on contact means there is no infection risk from discarded masks after use, removing any potential biohazard.
The effectiveness of the mask against the coronavirus and Influenza has been tested by an independent laboratory and a leading UK university. It has also received European regulatory approval and carries a CE mark, meaning it has been independently reviewed.
The Pro-Larva idea was developed by scientists at Pharm2Farm led by Dr Gareth Cave. Pharm2Farm recently installed a face mask production line in Nottingham, UK and are working with European and global face mask manufacturers to scale-up the supply of Pro-Larva to meet demand.
Dr Gareth Cave, founder of the technology and Pharm2Farm, added: “Helping healthcare professionals protect themselves, their co-workers and patients is very important, and we are keen to support the NHS. However, there are many other categories of frontline workers we are looking to engage with – from schools to care home workers, to the retail and leisure industries – who could benefit from this next generation mask.”
-Ends-
Notes to Editors
About Pharm2Farm
Pharm2Farm is a VC backed Nottingham Trent University spin-out which provides advanced nanoparticle-based solutions for plant, animal and human care through a patented novel production process. For more information, please visit the website: www.pharm2farm.org
About the Pro-Larva mask
The 4 ply anti-viral disposable medical mask from Pharm2Farm Ltd is proven to kill up to 99.9% of coronaviruses and 90% of influenza for up to 7 hours. The mask is splash resistant with a melt blown filter and hypoallergenic layers and uses Pharm2Farm’s proprietary α-virion™ virucidal technology, featuring copper nanoparticles. The Pro-Larva mask is CE marked and its α-virion™ layer has been certified to ISO 18184 standards. ISO 18184 is a standard protocol to quantify the antiviral properties of textile materials. For more information about Pro-Larva mask, its features and suppliers, please visit: https://pro-larva.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 16:30:00 CEST | Press release
Companies team to deliver a unified, enterprise-scale agentic stack to help organizations with managing data sovereignty and optimizing AI costs Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom